Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
🌎 Global
Global
United States
Australia
United Kingdom
Canada
India
China
Argentina
Austria
Bahrain
Bangladesh
Belgium
Bermuda
Botswana
Brazil
Bulgaria
Chile
Colombia
Croatia
Cyprus
Czech Republic
Denmark
Egypt
Estonia
Finland
France
Germany
Ghana
Greece
Hong Kong
Hungary
Iceland
Indonesia
Ireland
Israel
Italy
Ivory Coast
Jamaica
Japan
Jordan
Kenya
Kuwait
Latvia
Lithuania
Luxembourg
Malawi
Malaysia
Malta
Mauritius
Mexico
Morocco
Namibia
Netherlands
New Zealand
Nigeria
Norway
Oman
Pakistan
Palestinian Authority
Peru
Philippines
Poland
Portugal
Qatar
Romania
Russia
Saudi Arabia
Serbia
Singapore
Slovakia
Slovenia
South Africa
South Korea
Spain
Sri Lanka
Sweden
Switzerland
Taiwan
Tanzania
Thailand
Trinidad & Tobago
Tunisia
Turkey
Uganda
Ukraine
United Arab Emirates
Venezuela
Vietnam
Zambia
Zimbabwe
Create a narrative
Global Community
Our community narratives are driven by numbers and valuation.
Create a narrative
Community Investing Ideas
Global Weekly Picks
Airbnb
TI
TickerTickle
Community Contributor
Airbnb (ABNB): Still one of the most interesting bets in travel
Key insights Airbnb is changing from a travel-only app to a full lifestyle platform (stays, rentals, experiences) International markets are growing faster than the US, which is slowing down Product experience is improving a lot, with AI making search and booking easier Regulations are becoming a big risk, especially in Europe where listings are getting removed The way people move around the world has changed. It’s not only about holidays anymore.
View narrative
US$163.75
FV
23.9% undervalued
intrinsic discount
12.00%
Revenue growth p.a.
Set Fair Value
7
users have liked this narrative
0
users have commented on this narrative
30
users have followed this narrative
New
narrative
ING Groep
PI
PittTheYounger
Community Contributor
ING leads the pack when it comes to pivoting towards non-lending income
ING, of course, is a bank; and banks don't like falling interest rates, right? For the dominant stream of income is their core business model, i.e. borrowing short-term and lending long-term, reaping the difference in interest rates in the process.
View narrative
€27.92
FV
24.3% undervalued
intrinsic discount
9.00%
Revenue growth p.a.
Set Fair Value
4
users have liked this narrative
0
users have commented on this narrative
12
users have followed this narrative
New
narrative
Coles Group
RO
Robbo
Community Contributor
Coles (ASX: COL): Safe, Steady, and Surprisingly Cheap
The supermarket chain Coles is the kind of “boring” business that may have been overlooked as an investment opportunity. Although it was divested from Wesfarmers in 2018, Coles’ heritage traces back to 1914 — giving it over 110 years of history.
View narrative
AU$22.00
FV
4.1% undervalued
intrinsic discount
8.72%
Revenue growth p.a.
Set Fair Value
5
users have liked this narrative
2
users have commented on this narrative
14
users have followed this narrative
New
narrative
All companies
Popular
Undervalued
Overvalued
Load previous narratives
Coherus Oncology
AN
AnalystHighTarget
Consensus Narrative from 3 Analysts
Precision Medicine And Aging Markets Will Fuel Oncology Despite Setbacks
Key Takeaways Accelerated adoption, innovative pipeline, and first-to-market therapies may lead to higher-than-expected revenue growth and market leadership. Strategic international partnerships and focus on differentiated, precision oncology assets position the company for premium pricing, strong margins, and sustained global expansion.
View narrative
US$7.00
FV
85.7% undervalued
intrinsic discount
-21.16%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
New
narrative
Cardlytics
AN
AnalystHighTarget
Consensus Narrative from 4 Analysts
Digital Payments Adoption Will Expand Personalized Advertising In Fintech
Key Takeaways Cardlytics is positioned for accelerated growth through new partnerships, advanced analytics, and its unique access to large-scale transaction data. The platform's closed ecosystem and strong value proposition are set to drive advertiser budgets, margin expansion, and a greater share of loyalty-driven spending.
View narrative
US$3.00
FV
56.3% undervalued
intrinsic discount
-3.04%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
New
narrative
Hexagon Purus
AN
AnalystHighTarget
Consensus Narrative from 3 Analysts
US And German Incentives Will Expand Zero Emission Infrastructure
Key Takeaways Aggressive cost reductions and maintained production capacity position Hexagon Purus for rapid margin improvement and earnings rebound as market demand recovers. Portfolio diversification, strategic partnerships, and favorable policy shifts create multiple pathways for sustained revenue, recurring cash flow, and increased market resilience.
View narrative
NOK 6.20
FV
69.1% undervalued
intrinsic discount
48.41%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
New
narrative
SoundThinking
AN
AnalystHighTarget
Consensus Narrative from 6 Analysts
Urbanization And AI Will Redefine Global Public Safety
Key Takeaways Accelerating international adoption, pricing power in emerging markets, and legislative tailwinds could drive significant revenue and high-margin growth beyond current projections. Expanding SaaS model, cross-selling opportunities, and digital transformation leadership strengthen recurring revenues, lift margins, and increase long-term earnings visibility.
View narrative
US$29.86
FV
56.6% undervalued
intrinsic discount
10.47%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
New
narrative
Nektar Therapeutics
AN
AnalystHighTarget
Consensus Narrative from 6 Analysts
Immunotherapy Advances Will Serve Aging Demand Yet Face Regulatory Hurdles
Key Takeaways REZPEG is positioned to become a market leader in dermatology due to strong clinical data, expedited approval pathways, and potential broad patient reach. Nektar's solid financials and innovative technology platform offer undervalued growth potential, diversification, and appeal for strategic partnerships or acquisitions.
View narrative
US$120.00
FV
78.6% undervalued
intrinsic discount
-9.87%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
New
narrative
Sutro Biopharma
AN
AnalystHighTarget
Consensus Narrative from 7 Analysts
Cell-Free Platform Will Unlock Broad Personalized Oncology Opportunities
Key Takeaways Strategic focus on advanced ADC programs and external manufacturing partnerships positions Sutro for accelerated revenue growth, high margins, and reduced dilution risk. Proprietary cell-free platform and pipeline strength enable leadership in personalized oncology, supporting premium pricing, diverse partnerships, and substantial expansion opportunities.
View narrative
US$7.00
FV
89.0% undervalued
intrinsic discount
2.34%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
New
narrative
Biodesix
AN
AnalystHighTarget
Consensus Narrative from 4 Analysts
Precision Medicine And AI Will Fuel Diagnostic Evolution
Key Takeaways Expanding access to primary care and rapid clinical validation position Biodesix for outsized revenue growth, improved margins, and accelerated payer coverage, boosting profitability and cash flow. Integration of multi-omics, AI, and digital tools along with strong pharma partnerships drive platform dominance, recurring revenues, and sustained long-term earnings expansion.
View narrative
US$2.00
FV
80.8% undervalued
intrinsic discount
20.48%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
New
narrative
Alector
AN
AnalystHighTarget
Consensus Narrative from 7 Analysts
Global Aging And Genomics Will Unlock Neurodegeneration Breakthroughs
Key Takeaways Robust pipeline progress and regulatory alignment position the company for rapid market expansion, premium pricing, and outsized revenue growth in key neurodegeneration segments. Strong platform versatility and industry interest increase potential for quick commercialization, lucrative partnerships, and accelerated long-term earnings growth.
View narrative
US$10.00
FV
78.2% undervalued
intrinsic discount
52.37%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
New
narrative
Clarus
AN
AnalystHighTarget
Consensus Narrative from 6 Analysts
Outdoor Wellness And Adventure Trends Will Boost Demand
Key Takeaways Streamlined operations, premium product focus, and digital advancements are expected to boost margins and profitability beyond historical levels as macroeconomic pressures ease. Expanding international reach, new product launches, and increased consumer demand in outdoor activities position Clarus for sustained, above-industry revenue growth.
View narrative
US$6.82
FV
48.5% undervalued
intrinsic discount
4.16%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
New
narrative
Value any company in seconds
Popular companies